HIGH-GRADE B-CELL LYMPHOMA (HGBCL)
Clinical trials for HIGH-GRADE B-CELL LYMPHOMA (HGBCL) explained in plain language.
Never miss a new study
Get alerted when new HIGH-GRADE B-CELL LYMPHOMA (HGBCL) trials appear
Sign up with your email to follow new studies for HIGH-GRADE B-CELL LYMPHOMA (HGBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New 'Double Punch' CAR T-Cell therapy takes on tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new cell therapy called GF-CART01 for people with certain B-cell blood cancers (like lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two cancer markers (CD…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA (HGBCL)
Phase: PHASE1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA (HGBCL)
Phase: PHASE2, PHASE3 • Sponsor: Health Institutes of Turkey • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Last-Resort drug made available for lymphoma patients
Disease control AVAILABLEThis program provides compassionate use of odronextamab for people with relapsed or refractory follicular lymphoma, diffuse large B-cell lymphoma, or other B-cell non-Hodgkin lymphomas who have no other treatment options. Odronextamab is a drug that helps the immune system attack…
Matched conditions: HIGH-GRADE B-CELL LYMPHOMA (HGBCL)
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC